SAN DIEGO, Sept. 17, 2015 /PRNewswire/ -- Sequenom
Laboratories, a wholly owned subsidiary of Sequenom, Inc. (NASDAQ:
SQNM), a life sciences company committed to enabling healthier
lives through the development of innovative products and services,
announced today that it has signed a national agreement with
UnitedHealthcare Insurance Company, effective October 1, 2015, covering 43 million people
throughout the United States, to
provide the MaterniT21® PLUS, HerediT® CF
Carrier Screen and HerediT® UNIVERSAL Carrier Screen
laboratory-developed tests (LDT). The addition of this contract
brings the number of covered lives under agreement by Sequenom
Laboratories' diagnostic services to more than 200 million.
The MaterniT21 PLUS test reports on trisomy 21, 18, 13, 16 and
22, sex chromosome aneuploidies, fetal sex and select
microdeletions in single or multifetal gestations as early as 10
weeks in a pregnancy. Estimates suggest there are about 750,000
pregnancies at high risk for fetal chromosomal abnormalities each
year in the United
States.
The HerediT CF Carrier Screening test analyzes the most
clinically relevant mutations and variants related to cystic
fibrosis. The HerediT UNIVERSAL Carrier Screening test is a
comprehensive, customizable expanded test that screens for > 250
diseases and > 2,000 disease-causing mutations.
These tests are available exclusively through Sequenom
Laboratories as testing services provided to health care
professionals. To learn more about these tests, please
visit www.laboratories.sequenom.com.
About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is committed to enabling healthier
lives through the development of innovative products and services.
The Company serves patients and physicians by providing early
patient management information. To learn how Sequenom is
interpreting the genome to improve your life, visit
www.sequenom.com.
About Sequenom Laboratories
Sequenom Laboratories™, a CAP-accredited and
CLIA-certified molecular diagnostics laboratory, has developed a
broad range of laboratory tests, with a focus principally on
prenatal care. Branded under the names HerediT®
CF, HerediT® UNIVERSAL,
VisibiliT™, MaterniT21® PLUS,
MaterniT™ GENOME, and NextView™, these
molecular genetic laboratory-developed tests provide early patient
management information for obstetricians, geneticists, and maternal
fetal medicine specialists. Sequenom Laboratories is changing
the landscape in genetic diagnostics using proprietary cutting edge
technologies. Visit www.laboratories.sequenom.com and follow
@SequenomLabs.
SEQUENOM®, Sequenom Laboratories™,
HerediT® CF, HerediT® UNIVERSAL, VisibiliT™,
MaterniT21® PLUS, MaterniT™ GENOME, and NextView™ are
trademarks of Sequenom, Inc. All other trademarks and service marks
are the property of their respective owners.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, including the development of innovative products and
services. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Risks are
described more fully in the Company's filings with the Securities
and Exchange Commission, including without limitation the Company's
most recent Quarterly Report on Form 10-Q and other documents
subsequently filed with or furnished to the Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. The
Company undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
![SEQUENOM logo. SEQUENOM logo.](http://photos.prnewswire.com/prnvar/20040415/SQNMLOGO)
Logo - http://photos.prnewswire.com/prnh/20040415/SQNMLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sequenom-laboratories-announces-national-coverage-agreement-with-unitedhealthcare-insurance-company-for-prenatal-diagnostic-testing-services-300144750.html
SOURCE Sequenom, Inc.